Search

Your search keyword '"Cazzola, Mario"' showing total 113 results

Search Constraints

Start Over You searched for: Author "Cazzola, Mario" Remove constraint Author: "Cazzola, Mario" Publisher wiley Remove constraint Publisher: wiley
113 results on '"Cazzola, Mario"'

Search Results

4. PD‐L1 overexpression correlates withJAK2 ‐V617Fmutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

6. Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib

8. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

10. Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group

11. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

12. Ruxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasms

15. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms

16. The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera

17. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients

18. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

19. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma

20. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing‐Neel syndrome

23. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera

24. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia

25. A novel germlineJAK2mutation in familial myeloproliferative neoplasms

26. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

27. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

28. Monoclonal gammopathy of undetermined significance: a new proposal of workup

30. Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors

33. Clinical significance of genetic aberrations in secondary acute myeloid leukemia

34. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium

35. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies

36. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma

37. Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm

38. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo

40. Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome

44. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF

45. Blast phase of essential thrombocythemia: A single center study

46. Marked downregulation of the granulopoiesis regulatorLEF1is associated with disease progression in the myelodysplastic syndromes

Catalog

Books, media, physical & digital resources